XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Provided By GlobeNewswire
Last update: Dec 2, 2024
Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets
Read more at globenewswire.comXOMA ROYALTY CORP - XOMA 8 3/8 PERP
NASDAQ:XOMAO (9/9/2025, 8:19:03 PM)
25.55
+0.06 (+0.24%)
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
NASDAQ:XOMAP (9/9/2025, 8:19:03 PM)
27
+0.24 (+0.9%)
36.76
+1.16 (+3.26%)
Find more stocks in the Stock Screener
